MAPT and Alzheimer disease: Although several studies revealed an increase in CSF CHI3L1 levels, which correlated with CSF markers for tau and amyloid in AD [75, 76], we did not find a correlation between CHI3L1 levels/counts and neuritic and diffuse plaques or NFTs.